Kristen rat sarcoma virus (KRAS) G12F-positive non-small cell lung cancer mimicking KRAS G12C positivity: A case report

被引：0

作者：

Oi, Issei ^{[1
,2
]}

Ito, Takanori ^{[1
]}

Saito, Zentaro ^{[1
]}

Imakita, Takuma ^{[1
]}

Kanai, Osamu ^{[1
]}

Fujita, Kohei ^{[1
]}

Tachibana, Hiromasa ^{[1
]}

Mio, Tadashi ^{[1
]}

机构：

[1] Natl Hosp Org Kyoto Med Ctr, Ctr Resp Dis, Div Resp Med, Kyoto, Japan

[2] Natl Hosp Org Kyoto Med Ctr, Ctr Resp Dis, Div Resp Med, Fukakusa Mukaihata,Fushimi Ku, Kyoto 6128555, Japan

来源：

THORACIC CANCER | 2024年 / 15卷 / 03期

关键词：

AMOY; G12C; G12F; KRAS; ADENOCARCINOMAS; PATTERNS;

D O I：

10.1111/1759-7714.15171

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Searching for driver gene alteration is a prerequisite for chemotherapy of non-small cell lung cancer. Due to its high sensitivity and concordance rate, the Amoy Dx Pan Lung Cancer PCR panel has been approved and is widely used in Japan. In this report, we describe a case in which a positive result for Kristen rat sarcoma virus (KRAS) exon2 p.G12F, a rare KRAS mutation, may have led to a false-positive result for KRAS exon2 p.G12C on AMOY. Genetic analysis in this case was performed by LC-SCRUM-Asia.

引用

页码：271 / 273

页数：3

共 50 条

[1] KRAS G12C mutations in non-small cell lung cancer
Li, J. J.
Wu, X. J.
Farzin, M.
Bray, V.
Williamson, J.
Pal, A.
Yip, P. Y.
Hagelamin, A.
Ding, P.
Nindra, U.
Vinod, S.
French, B.
Chua, W.
Gupta, R.
Cooper, W. A.
Wang, B.
Lee, C. S.
HISTOPATHOLOGY, 2024, 85 : 25 - 25
[2] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico
Ilaria Ricciotti
Valentina Favorito
Sandra Vietti Michelina
Pietro Scaparone
Giulio Metro
Andrea De Giglio
Federica Pecci
Giuseppe Lamberti
Chiara Ambrogio
Biagio Ricciuti
Current Oncology Reports, 2023, 25 : 1017 - 1029
[3] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Di Federico, Alessandro
Ricciotti, Ilaria
Favorito, Valentina
Michelina, Sandra Vietti
Scaparone, Pietro
Metro, Giulio
De Giglio, Andrea
Pecci, Federica
Lamberti, Giuseppe
Ambrogio, Chiara
Ricciuti, Biagio
CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 1017 - 1029
[4] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Pinto, L. Masfarre
Parreira, A. S. D. F. M.
Unanua, N. Castro
Rocha, P.
Ruiz, I. Morilla
Sanchez, L. Teijeira
Clave, S.
Gorro, N. Navarro
Mora, R. Bach
Sanchez, I.
Campos, M. A. Galindo
Garcia, A. Taus
Martinez, A. Azkarate
Fabregat, R. Marse
Paricio, B. Bellosillo
Arasanz, H.
Aguillo, M. Martinez
Arriola, E.
ANNALS OF ONCOLOGY, 2023, 34
[5] Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, Wanyuan
Franchini, Fanny
Alexander, Marliese
Officer, Ann
Wong, Hui-Li
IJzerman, Maarten
Desai, Jayesh
Solomon, Benjamin J.
LUNG CANCER, 2020, 146 : 310 - 317
[6] Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Lee, Arnold
TARGETED ONCOLOGY, 2022, 17 (06) : 727 - 733
[7] Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Arnold Lee
Targeted Oncology, 2022, 17 : 727 - 733
[8] Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
Zheng, Xinting
Luo, Jiamin
Liu, Wei
Ashby, Charles R., Jr.
Chen, Zhe-Sheng
Lin, Lizhu
DRUGS OF TODAY, 2022, 58 (04) : 175 - 185
[9] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
Rosell, R.
Jain, A.
Codony-Servat, J.
Shivamallu, C.
Kollur, S. Prasad
Prasad, A.
Jantus-Lewintre, E.
Ito, M.
Cardona, A. F.
Arrieta, O.
Cao, P.
Cai, X.
Xing, B.
Pedraz-Valdunciel, C.
Dantes, Z.
Sullivan, I.
Aguilar, A.
Molina-Vila, M. A.
Gonzalez-Cao, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
[10] Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
Arnold Lee
Targeted Oncology, 2023, 18 : 177 - 177

← 1 2 3 4 5 →